Olaparib Dose Escalation in Combination With High Dose Radiotherapy to the Breast Andregional Lymph Nodes in Patients With Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2019
Price : $35 *
At a glance
- Drugs Olaparib (Primary)
- Indications Advanced breast cancer; Inflammatory breast cancer
- Focus Adverse reactions
- 26 Jun 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Sep 2019.
- 26 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 28 Sep 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2020.